4D Molecular Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for 4D Molecular Therapeutics (FDMT).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

12Buy

1Sell

Consensus RatingBuy# Analysts13Avg. Consensus PT$32Upside to Avg. PT+141.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	Chardan Capital	Gautam Chukka	PT Cut	Buy	$26→$25
Sep 29, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$29→$33
Sep 14, 2026	Cantor Fitzgerald	Josh Schimmer	Upgrade	Neutral→Overweight	$20
Jul 31, 2026	B. Riley Securities	Mayank Mamtani	Initiate	Buy	$37
Jul 20, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$36
Mar 30, 2026	Jefferies	Faisal Khurshid	Assumes	Buy	$40→$21
Mar 20, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$36
Mar 19, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$32→$35
Mar 19, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$26
Jan 28, 2026	Barclays	Eliana Merle	Initiate	Overweight	$33
Dec 18, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$26
Nov 11, 2025	RBC Capital	Lisa Walter	PT Raise	Outperform	$26→$32
Nov 11, 2025	Barclays	Gena Wang	PT Cut	Overweight	$38→$33
Nov 11, 2025	Chardan Capital	Geulah Livshits	PT Raise	Buy	$25→$26
Oct 21, 2025	RBC Capital	Lisa Walter	Maintained	Outperform	$26
Aug 12, 2025	Roth Capital	Salveen Richter	PT Cut	Buy	$44→$38
Aug 12, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$25
Aug 1, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$25
Jul 3, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$25
May 9, 2025	Chardan Capital	Geulah Livshits	PT Cut	Buy	$28→$25

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

Chardan Capital analyst Gautam Chukka maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $26 to $25.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33

B of A Securities analyst Tazeen Ahmad maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $29 to $33.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target

Cantor Fitzgerald analyst Josh Schimmer upgrades 4D Molecular Therapeutics (NASDAQ:FDMT) from Neutral to Overweight and announces $20 price target.

Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37

B. Riley Securities analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and announces Price Target of $37.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $36 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $36 price target.

Benzinga Newsdesk

4D Molecular Therapeutics Inc

4D Molecular Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

PRO
B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33

PRO
Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target

PRO
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37

PRO
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

People Also Watch

People Also Watch

4D Molecular Therapeutics Inc

4D Molecular Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROChardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

PROB of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33

PROCantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target

PROB. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37

PROHC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

PROHC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

People Also Watch

People Also Watch

PRO
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

PRO
B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33

PRO
Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target

PRO
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37

PRO
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target